Epigenetic modifications, particularly histone acetylation, have been implicated in Alzheimer's disease (AD). While previous studies have suggested that histone hypoacetylation may regulate the expression of genes associated with memory and learning in AD, little is known about histone regulation of AD-related genes such as Presenilin 1(PS1) and beta-site amyloid precursor protein cleaving enzyme 1(BACE1). By utilizing neuroblastoma N2a cells transfected with Swedish mutated human amyloid precursor protein (APP) (N2a/APPswe) and wild-type APP (N2a/APPwt) as cellular models of AD, we examined the alterations of histone acetylation at the promoter regions of PS1 and BACE1 in these cells. Our results revealed that histone H3 acetylation in PS1 and BACE1 promoters is markedly increased in N2a/APPswe cells when compared to N2a/APPwt cells and control cells (vector-transfected), respectively, causing the elevated expression of PS1 and BACE1. In addition, expression of histone acetyltransferase (HAT) adenoviral E1A-associated 300-kDa protein (p300) is dramatically enhanced in N2a/APPswe cells compared to N2a/APPwt and control cells. We have further demonstrated the direct binding of p300 protein to the PS1 and BACE1 promoters in N2a/APPswe cells. The expression levels of H3 acetylation of the PS1 and BACE1 promoters and p300 protein, however, were found to be not significantly different in N2a/APPwt cells when compared to controls in our studies. Furthermore, curcumin, a natural selective inhibitor of p300 in HATs, significantly suppressed the expression of PS1 and BACE1 through inhibition of H3 acetylation in their promoter regions in N2a/APPswe cells. These findings indicated that histone acetyltransferase p300 plays a critical role in controlling the expression of AD-related genes through regulating the acetylation of their promoter regions, suggesting that p300 may represent a novel potential therapeutic target for AD.
References
[1]
Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430: 631–639. doi: 10.1038/nature02621
[2]
Miller G (2010) Epigenetics. A role for epigenetics in cognition. Science 329: 27. doi: 10.1126/science.329.5987.27
[3]
Graff J, Rei D, Guan JS, Wang WY, Seo J, et al. (2012) An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483: 222–226. doi: 10.1038/nature10849
[4]
Peleg S, Sananbenesi F, Zovoilis A, Burkhardt S, Bahari-Javan S, et al. (2010) Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328: 753–756. doi: 10.1126/science.1186088
[5]
Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, et al. (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459: 55–60. doi: 10.1038/nature07925
[6]
Kaelin WG Jr, McKnight SL (2013) Influence of metabolism on epigenetics and disease. Cell 153: 56–69. doi: 10.1016/j.cell.2013.03.004
[7]
Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, et al. (2003) A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 114: 635–645. doi: 10.1016/j.cell.2003.08.008
[8]
Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, et al. (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42: 23–36. doi: 10.1016/s0896-6273(04)00182-5
[9]
Marques SC, Lemos R, Ferreiro E, Martins M, de Mendonca A, et al. (2012) Epigenetic regulation of BACE1 in Alzheimer's disease patients and in transgenic mice. Neuroscience 220: 256–266. doi: 10.1016/j.neuroscience.2012.06.029
[10]
Graff J, Mansuy IM (2009) Epigenetic dysregulation in cognitive disorders. Eur J Neurosci 30: 1–8. doi: 10.1111/j.1460-9568.2009.06787.x
[11]
Gu X, Sun J, Li S, Wu X, Li L (2013) Oxidative stress induces DNA demethylation and histone acetylation in SH-SY5Y cells: potential epigenetic mechanisms in gene transcription in Abeta production. Neurobiol Aging 34: 1069–1079. doi: 10.1016/j.neurobiolaging.2012.10.013
[12]
Guo X, Wu X, Ren L, Liu G, Li L (2011) Epigenetic mechanisms of amyloid-beta production in anisomycin-treated SH-SY5Y cells. Neuroscience 194: 272–281. doi: 10.1016/j.neuroscience.2011.07.012
[13]
Rouaux C, Jokic N, Mbebi C, Boutillier S, Loeffler JP, et al. (2003) Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J 22: 6537–6549. doi: 10.1093/emboj/cdg615
[14]
Oliveira AM, Wood MA, McDonough CB, Abel T (2007) Transgenic mice expressing an inhibitory truncated form of p300 exhibit long-term memory deficits. Learn Mem 14: 564–572. doi: 10.1101/lm.656907
[15]
Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS (1996) Metabolism of the “Swedish” amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the “beta-secretase” site occurs in the golgi apparatus. J Biol Chem 271: 9390–9397. doi: 10.1074/jbc.271.16.9390
[16]
Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, et al. (2008) The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 118: 868–878. doi: 10.1172/jci33160
[17]
Xia X, Cai H, Qin S, Xu C (2012) Histone acetylase inhibitor curcumin impairs mouse spermiogenesis-an in vitro study. PLoS One 7: e48673. doi: 10.1371/journal.pone.0048673
[18]
Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, et al. (1998) Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 4: 447–451. doi: 10.1038/nm0498-447
[19]
Chen S, Feng B, George B, Chakrabarti R, Chen M, et al. (2010) Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells. Am J Physiol Endocrinol Metab 298: E127–137. doi: 10.1152/ajpendo.00432.2009
[20]
Wang Z, Yang D, Zhang X, Li T, Li J, et al. (2011) Hypoxia-induced down-regulation of neprilysin by histone modification in mouse primary cortical and hippocampal neurons. PLoS One 6: e19229. doi: 10.1371/journal.pone.0019229
[21]
Coulson DT, Beyer N, Quinn JG, Brockbank S, Hellemans J, et al. (2010) BACE1 mRNA expression in Alzheimer's disease postmortem brain tissue. J Alzheimers Dis 22: 1111–1122.
[22]
Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, et al. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316: 750–754. doi: 10.1126/science.1141736
[23]
Theuns J, Van Broeckhoven C (2000) Transcriptional regulation of Alzheimer's disease genes: implications for susceptibility. Hum Mol Genet 9: 2383–2394. doi: 10.1093/hmg/9.16.2383
[24]
Bousiges O, Vasconcelos AP, Neidl R, Cosquer B, Herbeaux K, et al. (2010) Spatial memory consolidation is associated with induction of several lysine-acetyltransferase (histone acetyltransferase) expression levels and H2B/H4 acetylation-dependent transcriptional events in the rat hippocampus. Neuropsychopharmacology 35: 2521–2537. doi: 10.1038/npp.2010.117
[25]
Chami L, Buggia-Prevot V, Duplan E, Delprete D, Chami M, et al. (2012) Nuclear factor-kappaB regulates betaAPP and beta- and gamma-secretases differently at physiological and supraphysiological Abeta concentrations. J Biol Chem 287: 24573–24584. doi: 10.1074/jbc.m111.333054
[26]
Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K (2004) Regulation of cellular response to oncogenic and oxidative stress by Seladin-1. Nature 432: 640–645. doi: 10.1038/nature03173
[27]
Liu R, Lei JX, Luo C, Lan X, Chi L, et al. (2012) Increased EID1 nuclear translocation impairs synaptic plasticity and memory function associated with pathogenesis of Alzheimer's disease. Neurobiol Dis 45: 902–912. doi: 10.1016/j.nbd.2011.12.007
[28]
Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, et al. (2004) Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 279: 51163–51171. doi: 10.1074/jbc.m409024200
[29]
Sun H, Yang X, Zhu J, Lv T, Chen Y, et al. (2010) Inhibition of p300-HAT results in a reduced histone acetylation and down-regulation of gene expression in cardiac myocytes. Life Sci 87: 707–714. doi: 10.1016/j.lfs.2010.10.009
[30]
Belkacemi A, Doggui S, Dao L, Ramassamy C (2011) Challenges associated with curcumin therapy in Alzheimer disease. Expert Rev Mol Med 13: e34. doi: 10.1017/s1462399411002055
[31]
Wang HM, Zhao YX, Zhang S, Liu GD, Kang WY, et al. (2010) PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes. J Alzheimers Dis 20: 1189–1199.
[32]
Zhang C, Browne A, Child D, Tanzi RE (2010) Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem 285: 28472–28480. doi: 10.1074/jbc.m110.133520
[33]
Goodman RH, Smolik S (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14: 1553–1577.
